Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

The XGBoost model predicts hyperglycemia risk in psoriasis patients with high accuracy, achieving an AUC of 0.821 in the training set. A web-based calculator was developed to facilitate personalized ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...

A recent Phase 3 clinical trial demonstrated that a steroid-free topical foam, roflumilast (Zoryve), significantly improved the signs and symptoms of psoriasis on both the scalp and body. The foam ...

Any practitioner who cares for patients with psoriasis should be familiar with and make use of systemic therapies. These medications are clearly indicated for patients who have diffuse disease where ...